Topics:

Kidney Cancer

New Target for Fighting Clear Cell RCC?

Scientists have discovered a new molecular target for therapy to fight clear cell renal cell carcinoma, neuronal pentraxin 2 (NPTX2).

Kidney Cancer

Patient exposure to metformin before undergoing nephrectomy for renal cell carcinoma may have an effect on patient survival, according to a new study.

Preoperative levels of C-reactive protein may be as predictive of outcomes as pathological TNM stage or tumor grade for prognosis in renal cell carcinoma.

A new study shows yet another link between increasing body mass index (BMI) and the risk of several common cancers, including kidney cancer.

Expression of microRNA (miR)-23b/27b cluster has been linked with increased risk for clear cell RCC disease progression, and may be a predictor of poor survival.

Researchers have identified a key gluconeogenic enzyme, the absence of which in clear cell renal cell carcinoma (RCC) may explain the uncontrolled cell growth present in cancer cells compared with normal kidney cells.

Results of a head-to-head comparison of first-line treatment of metastatic renal cell carcinoma with the mTOR inhibitor everolimus or VEGF inhibitor sunitinib showed that everolimus did not meet noninferiority requirements as a first-line therapy.

Scientists have discovered a new molecular target for therapy to fight clear cell renal cell carcinoma, neuronal pentraxin 2 (NPTX2).

Pages

Subscribe to Kidney Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.